Inozyme Pharma Inc (INZY)
3.42
-0.13
(-3.66%)
USD |
NASDAQ |
Nov 14, 16:00
3.50
+0.08
(+2.34%)
After-Hours: 20:00
Inozyme Pharma Enterprise Value: 142.09M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 142.09M |
| November 12, 2024 | 155.58M |
| November 11, 2024 | 171.00M |
| November 08, 2024 | 172.28M |
| November 07, 2024 | 177.42M |
| November 06, 2024 | 185.77M |
| November 05, 2024 | 175.49M |
| November 04, 2024 | 197.98M |
| November 01, 2024 | 194.12M |
| October 31, 2024 | 189.63M |
| October 30, 2024 | 205.69M |
| October 29, 2024 | 210.82M |
| October 28, 2024 | 220.81M |
| October 25, 2024 | 221.45M |
| October 24, 2024 | 229.15M |
| October 23, 2024 | 228.51M |
| October 22, 2024 | 241.99M |
| October 21, 2024 | 252.90M |
| October 18, 2024 | 269.59M |
| October 17, 2024 | 244.56M |
| October 16, 2024 | 254.83M |
| October 15, 2024 | 258.68M |
| October 14, 2024 | 250.98M |
| October 11, 2024 | 246.48M |
| October 10, 2024 | 230.44M |
| Date | Value |
|---|---|
| October 09, 2024 | 241.99M |
| October 08, 2024 | 250.98M |
| October 07, 2024 | 249.05M |
| October 04, 2024 | 245.84M |
| October 03, 2024 | 238.78M |
| October 02, 2024 | 236.86M |
| October 01, 2024 | 236.21M |
| September 30, 2024 | 249.69M |
| September 27, 2024 | 248.38M |
| September 26, 2024 | 245.70M |
| September 25, 2024 | 246.37M |
| September 24, 2024 | 251.74M |
| September 23, 2024 | 253.08M |
| September 20, 2024 | 285.29M |
| September 19, 2024 | 288.64M |
| September 18, 2024 | 290.65M |
| September 17, 2024 | 292.00M |
| September 16, 2024 | 302.73M |
| September 13, 2024 | 303.40M |
| September 12, 2024 | 277.90M |
| September 11, 2024 | 250.39M |
| September 10, 2024 | 253.75M |
| September 09, 2024 | 245.03M |
| September 06, 2024 | 234.96M |
| September 05, 2024 | 251.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-94.96M
Minimum
Dec 30 2022
641.75M
Maximum
Sep 01 2020
165.01M
Average
157.67M
Median
Apr 19 2024
Enterprise Value Benchmarks
| Tango Therapeutics Inc | 89.13M |
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 3.432M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.57M |
| Total Expenses (Quarterly) | 24.85M |
| EPS Diluted (Quarterly) | -0.39 |
| Earnings Yield | -45.61% |